Initial relapse in patients with NSCLC (NSCLC), characterized by the emergence of osimertinib drug resistance, represents a significant challenge in its treatment.In the treatment of EGFR-mutation-positive NSCLC (NSCLC), the third-generation EGFR TKI (TKI) osimertinib has demonstrated significant effectiveness.However, drug resistance to osimertinib typically develops, resulting in disease advancement and reoccurrence.This article explores the concept of osimertinib drug resistance groups, which focus on Initial relapse drivers. It delves into the basic mechanisms, identifies potential therapeutic strategies, and emphasizes the importance of personalized medicine in the treatment of NSCLC.1. Understanding the Mechanisms…
